SG11201606819QA - Compositions for the inactivation of virus replication and methods of making and using the same - Google Patents
Compositions for the inactivation of virus replication and methods of making and using the sameInfo
- Publication number
- SG11201606819QA SG11201606819QA SG11201606819QA SG11201606819QA SG11201606819QA SG 11201606819Q A SG11201606819Q A SG 11201606819QA SG 11201606819Q A SG11201606819Q A SG 11201606819QA SG 11201606819Q A SG11201606819Q A SG 11201606819QA SG 11201606819Q A SG11201606819Q A SG 11201606819QA
- Authority
- SG
- Singapore
- Prior art keywords
- inactivation
- compositions
- making
- methods
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461940883P | 2014-02-18 | 2014-02-18 | |
PCT/US2015/016354 WO2015126927A2 (en) | 2014-02-18 | 2015-02-18 | Compositions for the inactivation of virus replication and methods of making and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201606819QA true SG11201606819QA (en) | 2016-09-29 |
Family
ID=53879230
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201606819QA SG11201606819QA (en) | 2014-02-18 | 2015-02-18 | Compositions for the inactivation of virus replication and methods of making and using the same |
Country Status (14)
Country | Link |
---|---|
US (2) | US10286084B2 (en) |
EP (1) | EP3107999A4 (en) |
JP (1) | JP2017506893A (en) |
KR (1) | KR20160130392A (en) |
CN (1) | CN106232823A (en) |
AU (1) | AU2015219167A1 (en) |
BR (1) | BR112016019068A2 (en) |
CA (1) | CA2940084A1 (en) |
IL (1) | IL247309A0 (en) |
MX (1) | MX2016010781A (en) |
PH (1) | PH12016501623A1 (en) |
RU (1) | RU2016136977A (en) |
SG (1) | SG11201606819QA (en) |
WO (1) | WO2015126927A2 (en) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103517990A (en) | 2010-10-07 | 2014-01-15 | 通用医疗公司 | Biomarkers of cancer |
AU2012333134B2 (en) | 2011-07-22 | 2017-05-25 | John Paul Guilinger | Evaluation and improvement of nuclease cleavage specificity |
WO2014113493A1 (en) | 2013-01-16 | 2014-07-24 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
WO2015070083A1 (en) | 2013-11-07 | 2015-05-14 | Editas Medicine,Inc. | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS |
US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
EP3160980B1 (en) * | 2014-05-28 | 2020-05-20 | The Regents of the University of California | HYBRID tRNA/pre-miRNA MOLECULES AND METHODS OF USE |
AU2015266776A1 (en) | 2014-05-30 | 2016-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods of delivering treatments for latent viral infections |
AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
MA41349A (en) * | 2015-01-14 | 2017-11-21 | Univ Temple | RNA-GUIDED ERADICATION OF HERPES SIMPLEX TYPE I AND OTHER ASSOCIATED HERPES VIRUSES |
WO2016130600A2 (en) | 2015-02-09 | 2016-08-18 | Duke University | Compositions and methods for epigenome editing |
EP3324999A1 (en) * | 2015-05-29 | 2018-05-30 | Agenovir Corporation | Compositions and methods for cell targeted hpv treatment |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
US10626393B2 (en) | 2015-06-04 | 2020-04-21 | Arbutus Biopharma Corporation | Delivering CRISPR therapeutics with lipid nanoparticles |
WO2016197132A1 (en) * | 2015-06-04 | 2016-12-08 | Protiva Biotherapeutics Inc. | Treating hepatitis b virus infection using crispr |
WO2017015637A1 (en) | 2015-07-22 | 2017-01-26 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
MX2018002339A (en) | 2015-08-25 | 2018-12-19 | Univ Duke | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases. |
US20170087224A1 (en) * | 2015-09-29 | 2017-03-30 | Agenovir Corporation | Delivery methods and compositions |
WO2017058791A1 (en) * | 2015-09-29 | 2017-04-06 | Agenovir Corporation | Compositions and methods for treatment of latent viral infections |
WO2017058795A1 (en) * | 2015-09-29 | 2017-04-06 | Agenovir Corporation | Compositions and methods for latent viral transcription regulation |
US11970710B2 (en) | 2015-10-13 | 2024-04-30 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
JP7408284B2 (en) | 2015-10-30 | 2024-01-05 | エディタス・メディシン、インコーポレイテッド | CRISPR/CAS-related methods and compositions for treating herpes simplex virus |
WO2017105991A1 (en) * | 2015-12-18 | 2017-06-22 | Danisco Us Inc. | Methods and compositions for t-rna based guide rna expression |
US20190038770A1 (en) * | 2016-01-25 | 2019-02-07 | Excision Biotherapeutics,Inc. | Rna guided eradication of human jc virus and other polyomaviruses |
US20190127713A1 (en) * | 2016-04-13 | 2019-05-02 | Duke University | Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US20200095586A1 (en) * | 2016-06-01 | 2020-03-26 | Excision Biotherapeutics, Inc. | Compositions and methods of treatment for lytic and lysogenic viruses |
CN109640946A (en) * | 2016-06-03 | 2019-04-16 | 天普大学-联邦高等教育系统 | The negative-feedback regu- lation of HIV-1 is carried out by gene editing strategy |
WO2017223248A1 (en) * | 2016-06-21 | 2017-12-28 | University Of Florida Research Foundation, Inc. | Method for delivering rna to neurons to treat herpes infections |
CA3032699A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
WO2018081504A1 (en) | 2016-10-28 | 2018-05-03 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating herpes simplex virus |
EP3559231B1 (en) | 2016-11-11 | 2022-08-17 | Bio-Rad Laboratories, Inc. | Methods for processing nucleic acid samples |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
TW201839136A (en) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | Compositions and methods for the treatment of hemoglobinopathies |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
JP2020510439A (en) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Base-editing factor from cytosine to guanine |
US11674138B2 (en) | 2017-03-13 | 2023-06-13 | President And Fellows Of Harvard College | Methods of modulating expression of target nucleic acid sequences in a cell |
EP3600382A4 (en) * | 2017-03-21 | 2020-12-30 | Anthony P. Shuber | Treating cancer with cas endonuclease complexes |
KR102687373B1 (en) | 2017-03-23 | 2024-07-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Nucleobase editing agent comprising a nucleic acid programmable DNA binding protein |
EP3601568A1 (en) * | 2017-03-31 | 2020-02-05 | Agenovir Corporation | Antiviral therapeutic |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
WO2018237369A2 (en) * | 2017-06-23 | 2018-12-27 | Vical Incorporated | Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection |
EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
JP7207665B2 (en) | 2017-08-04 | 2023-01-18 | 北京大学 | TALE RVDs that specifically recognize DNA bases modified by methylation and uses thereof |
CN111278983A (en) | 2017-08-08 | 2020-06-12 | 北京大学 | Gene knockout method |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
CN109468319A (en) * | 2017-09-08 | 2019-03-15 | 中山大学 | For inhibiting HSV-1 to replicate and/or CRISPR/Cas9 system, method, kit and its application of target sequence expression |
CN109468318A (en) * | 2017-09-08 | 2019-03-15 | 中山大学 | For inhibiting HSV-1 to replicate and/or CRISPR/Cas9 system, method, kit and its application of target sequence expression |
CN107557394A (en) * | 2017-09-29 | 2018-01-09 | 南京鼓楼医院 | The method for reducing embryonic gene editor's miss rate of CRISPR/Cas9 mediations |
CN111757937A (en) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | Use of adenosine base editor |
WO2019079755A1 (en) | 2017-10-20 | 2019-04-25 | Research Institute At Nationwide Children's Hospital | Methods and materials for nt-3 gene therapy |
EP3746556A1 (en) * | 2018-02-01 | 2020-12-09 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating herpes simplex virus (hsv) related keratitis |
CN111971389A (en) * | 2018-03-27 | 2020-11-20 | 苏州克睿基因生物科技有限公司 | Application of CRISPR/Cas system in gene editing |
EP3790969A1 (en) * | 2018-05-09 | 2021-03-17 | DSM IP Assets B.V. | Crispr transient expression construct (ctec) |
TW202039845A (en) * | 2018-12-20 | 2020-11-01 | 北京大學 | Compositions and methods for highly efficient genetic screening using barcoded guide rna constructs |
CN113646434B (en) * | 2018-12-20 | 2023-05-30 | 北京大学 | Compositions and methods for efficient gene screening using tagged guide RNA constructs |
US20220110963A1 (en) * | 2019-01-02 | 2022-04-14 | The General Hospital Corporation | Reverse transcriptase blocking agents and methods of using the same |
EP3918071A1 (en) * | 2019-02-01 | 2021-12-08 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions targeting virus genomes |
WO2020191249A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
AU2020258778A1 (en) * | 2019-04-18 | 2021-11-11 | Handong Global University Industry-Academic Cooperation Foundation | Composition and method for inhibiting proliferation of hepatitis B virus |
CN111139240B (en) * | 2020-01-20 | 2022-03-15 | 武汉大学 | Modified CRISPR/SaCas9 system targeting hepatitis B virus and application thereof |
US20230122226A1 (en) * | 2020-03-05 | 2023-04-20 | Board Of Regents Of The University Of Nebraska | Crispr/cas9 system for multistrain hiv-1 treatment |
MX2022014008A (en) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence. |
WO2024119102A1 (en) * | 2022-12-01 | 2024-06-06 | Locanabio, Inc. | Adeno-associated viral vectors for proper packaging of repetitive elements |
WO2024124416A1 (en) * | 2022-12-14 | 2024-06-20 | Wuhan Institute Of Virology, Chinese Academy Of Sciences | Engineered murine cytomegalovirus-derived tool virus, method of producing the same and applications thereof |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7090976B2 (en) * | 1999-11-10 | 2006-08-15 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising Renilla GFP |
US20080318210A1 (en) | 2003-08-27 | 2008-12-25 | Rosetta Genomics | Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof |
WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
US7795419B2 (en) * | 2004-05-26 | 2010-09-14 | Rosetta Genomics Ltd. | Viral and viral associated miRNAs and uses thereof |
RU2007135164A (en) * | 2005-02-23 | 2009-03-27 | Эйдженси Фор Сайенс, Текнолоджи Энд Рисерч (Sg) | IMMORTALIZED FEEDER CELLS |
US20080193563A1 (en) * | 2006-08-01 | 2008-08-14 | Rush University Medical Center | Harnessing wnt signaling to restrict hiv replication |
WO2009006584A2 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Colorado | Methods and compositions for identifying cellular rna transcripts |
US8815779B2 (en) * | 2009-09-16 | 2014-08-26 | SwitchGear Genomics, Inc. | Transcription biomarkers of biological responses and methods |
WO2012006551A2 (en) * | 2010-07-08 | 2012-01-12 | The Brigham And Women's Hospital, Inc. | Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules |
EP2694685B1 (en) * | 2011-04-08 | 2019-01-09 | Azzazy, Hassan, Mohamed, Ei-said | Detection of nucleic acids using unmodified gold nanoparticles |
US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
DK2800811T3 (en) * | 2012-05-25 | 2017-07-17 | Univ Vienna | METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION |
DE202013012610U1 (en) | 2012-10-23 | 2017-11-24 | Toolgen, Inc. | A composition for cleaving a target DNA comprising a guide RNA specific for the target DNA and a Cas protein-encoding nucleic acid or Cas protein, and their use |
WO2014089290A1 (en) | 2012-12-06 | 2014-06-12 | Sigma-Aldrich Co. Llc | Crispr-based genome modification and regulation |
DK2921557T3 (en) | 2012-12-12 | 2016-11-07 | Broad Inst Inc | Design of systems, methods and optimized sequence manipulation guide compositions |
EP3825401A1 (en) | 2012-12-12 | 2021-05-26 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
US8993233B2 (en) | 2012-12-12 | 2015-03-31 | The Broad Institute Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
ES2598115T3 (en) | 2012-12-12 | 2017-01-25 | The Broad Institute, Inc. | Systems engineering, methods and guide compositions optimized for sequence manipulation |
ES2658401T3 (en) | 2012-12-12 | 2018-03-09 | The Broad Institute, Inc. | Supply, modification and optimization of systems, methods and compositions for the manipulation of sequences and therapeutic applications |
AU2013359212B2 (en) * | 2012-12-12 | 2017-01-19 | Massachusetts Institute Of Technology | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
CN103233028B (en) * | 2013-01-25 | 2015-05-13 | 南京徇齐生物技术有限公司 | Specie limitation-free eucaryote gene targeting method having no bio-safety influence and helical-structure DNA sequence |
EP2970949B1 (en) * | 2013-03-15 | 2018-05-30 | MedImmune Limited | Novel nucleic acid molecules |
EA037850B1 (en) * | 2013-08-29 | 2021-05-27 | Тэмпл Юниверсити Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Methods and compositions for rna-guided treatment of hiv infection |
AU2014361784A1 (en) * | 2013-12-12 | 2016-06-23 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for HBV and viral diseases and disorders |
EP3207139A1 (en) * | 2014-10-17 | 2017-08-23 | The Penn State Research Foundation | Methods and compositions for multiplex rna guided genome editing and other rna technologies |
-
2015
- 2015-02-18 AU AU2015219167A patent/AU2015219167A1/en not_active Abandoned
- 2015-02-18 MX MX2016010781A patent/MX2016010781A/en unknown
- 2015-02-18 KR KR1020167024987A patent/KR20160130392A/en unknown
- 2015-02-18 CA CA2940084A patent/CA2940084A1/en not_active Abandoned
- 2015-02-18 BR BR112016019068A patent/BR112016019068A2/en not_active Application Discontinuation
- 2015-02-18 JP JP2016552891A patent/JP2017506893A/en active Pending
- 2015-02-18 RU RU2016136977A patent/RU2016136977A/en not_active Application Discontinuation
- 2015-02-18 SG SG11201606819QA patent/SG11201606819QA/en unknown
- 2015-02-18 US US15/119,867 patent/US10286084B2/en active Active
- 2015-02-18 WO PCT/US2015/016354 patent/WO2015126927A2/en active Application Filing
- 2015-02-18 EP EP15751819.2A patent/EP3107999A4/en not_active Withdrawn
- 2015-02-18 CN CN201580017543.7A patent/CN106232823A/en active Pending
-
2016
- 2016-08-15 PH PH12016501623A patent/PH12016501623A1/en unknown
- 2016-08-17 IL IL247309A patent/IL247309A0/en unknown
-
2019
- 2019-05-10 US US16/409,406 patent/US20190351070A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015126927A2 (en) | 2015-08-27 |
KR20160130392A (en) | 2016-11-11 |
IL247309A0 (en) | 2016-09-29 |
MX2016010781A (en) | 2017-02-15 |
US20190351070A1 (en) | 2019-11-21 |
WO2015126927A3 (en) | 2015-11-19 |
CN106232823A (en) | 2016-12-14 |
RU2016136977A (en) | 2018-03-20 |
US10286084B2 (en) | 2019-05-14 |
BR112016019068A2 (en) | 2017-10-10 |
US20170049909A1 (en) | 2017-02-23 |
AU2015219167A2 (en) | 2017-04-13 |
PH12016501623A1 (en) | 2016-11-07 |
EP3107999A4 (en) | 2017-10-04 |
JP2017506893A (en) | 2017-03-16 |
AU2015219167A1 (en) | 2016-09-08 |
EP3107999A2 (en) | 2016-12-28 |
CA2940084A1 (en) | 2015-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL247309A0 (en) | Compositions for the inactivation of virus replication and methods of making and using the same | |
HRP20192145T1 (en) | Carrier-antibody compositions and methods of making and using the same | |
ZA201707303B (en) | Compositions and methods for the treatment of immunodeficiency | |
HUE056172T2 (en) | Compositions of selenoorganic compounds and methods of use thereof | |
EP3209298A4 (en) | Compositions and methods for treating insomnia | |
IL246879A0 (en) | Apilimod compositions and methods for using same | |
EP3182989A4 (en) | Methods and compositions for the prevention and treatment of disease | |
EP3139928A4 (en) | Anordrin compositions and methods for treating diseases | |
EP3194564A4 (en) | Trichoderma compositions and methods of use | |
EP3166892A4 (en) | Scale-inhibition compositions and methods of making and using the same | |
EP3190886A4 (en) | Compositions and methods of use thereof | |
EP3198275A4 (en) | Sterilization compositions and methods | |
EP3204426A4 (en) | Compositions and methods for treating viral hemorrhagic fever | |
EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
IL251736B (en) | Methods and compositions for the treatment of radiation-related disorders | |
EP3341006A4 (en) | Compositions and methods for the treatment of neurodamage | |
IL246643B (en) | Compositions and kits for treating human immunodeficiency virus/accquired immunodeficiency syndrome | |
PT3113774T (en) | Compositions of grapiprant and methods for using the same | |
HK1243404A1 (en) | Tryptamide compositions and methods of use | |
EP3139744A4 (en) | Methods and compositions for treating and preventing tinnitus | |
EP3230254A4 (en) | Compositions and methods for treating diseases and conditions | |
GB2537518B (en) | Settable compositions and methods of use | |
AU2014905067A0 (en) | Compositions and methods of use | |
AU2014902829A0 (en) | Compositions and Methods of Use | |
GB201419559D0 (en) | Therapeutic compositions and methods |